Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Issue 2 (20th January 2016)

• Record Type: Journal Article
• Authors: Ryan, Aoife M.; Power, Derek G.; Daly, Louise; Cushen, Samantha J.; Ní Bhuachalla, Ēadaoin; Prado, Carla M.
• Is Part Of: Proceedings of the Nutrition Society. Volume 75:Issue 2(2016)
• Page Start: 199
• Page End: 211
• Publication Date: 2016-01-20
• Subjects: Cancer, -- Cachexia, -- Sarcopenia, -- Quality of life, -- Malnutrition, -- Survival; Nutrition -- Congresses; 612.30993
• DOI: 10.1017/S002966511500419X
• Languages: English
• ISSNs: 0029-6651

Abstract

Abstract : An awareness of the importance of nutritional status in hospital settings began more than 40 years ago. Much has been learned since and has altered care. For the past 40 years several large studies have shown that cancer patients are amongst the most malnourished of all patient groups. Recently, the use of gold-standard methods of body composition assessment, including computed tomography, has facilitated the understanding of the true prevalence of cancer cachexia (CC). CC remains a devastating syndrome affecting 50–80 % of cancer patients and it is responsible for the death of at least 20 %. The aetiology is multifactorial and complex; driven by pro-inflammatory cytokines and specific tumour-derived factors, which initiate an energy-intensive acute phase protein response and drive the loss of skeletal muscle even in the presence of adequate food intake and insulin. The most clinically relevant phenotypic feature of CC is muscle loss (sarcopenia), as this relates to asthenia, fatigue, impaired physical function, reduced tolerance to treatments, impaired quality of life and reduced survival. Sarcopenia is present in 20–70 % depending on the tumour type. There is mounting evidence that sarcopenia increases the risk of toxicity to many chemotherapy drugs. However, identification of patients with muscle loss has become increasingly difficult as 40–60 % of cancer patients are overweight or obese, even in the setting of metastatic disease. Further challenges exist in trying to reverse CC and sarcopenia. Future clinical trials investigating dose reductions in sarcopenic patients and dose-escalating studies based on pre-treatment body composition assessment have the potential to alter cancer treatment paradigms.